#1 Clinical Trials Search in Europe

Lenzumestrocel

Lenzumestrocel, an innovative cell therapy, is currently being studied in clinical trials for its potential to treat knee cartilage defects. This advanced therapy medical product, also known as BiCure ortho MSCp, uses autologous bone marrow-derived mesenchymal stem cells to potentially repair damaged cartilage in the knee joint. The ongoing research aims to evaluate the efficacy and safety of this treatment compared to conventional methods.

Table of Contents

What is LENZUMESTROCEL?

LENZUMESTROCEL is an advanced medical treatment that uses autologous bone marrow-derived mesenchymal stem cells. “Autologous” means the cells come from your own body, specifically from your bone marrow. These cells are then expanded (increased in number) in a laboratory and used to treat certain medical conditions.[1]

This treatment is also known by several other names, including:[1]

  • NEURONATA-R
  • Human culture expanded autologous mesenchymal stromal cells
  • Autologous bone marrow derived mesenchymal stem cells, expanded

Medical Conditions Treated

LENZUMESTROCEL is being studied for the treatment of knee cartilage defects. This condition is also referred to as:[1]

  • Articular cartilage defect
  • Cartilage damage
  • Cartilage repair

These terms all refer to damage or wear in the cartilage that covers the ends of the bones in your knee joint. This cartilage helps your knee move smoothly and cushions the bones. When it’s damaged, it can cause pain and difficulty moving.

How LENZUMESTROCEL Works

LENZUMESTROCEL is a type of cell therapy. The treatment involves taking your own stem cells, growing more of them in a lab, and then placing them back into your body where they’re needed. In this case, the cells are placed onto a 3D scaffold (a structure that supports cell growth) and then applied to the damaged area in your knee.[1]

The stem cells are believed to help repair the damaged cartilage by:

  • Developing into new cartilage cells
  • Promoting healing in the surrounding tissue
  • Reducing inflammation

Clinical Trial Details

LENZUMESTROCEL is currently being studied in a Phase IIb clinical trial. This means it has already shown promise in earlier studies, and researchers are now testing it in a larger group of people to better understand its effectiveness and safety.[1]

The main goal of this trial is to compare two treatments:[1]

  1. Conventional microfracture (a surgical technique to repair cartilage) plus a 3D scaffold with LENZUMESTROCEL
  2. Conventional microfracture plus a 3D scaffold alone

Researchers want to see if adding LENZUMESTROCEL to the standard treatment leads to better results for patients with knee cartilage defects.

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key requirements include:[1]

  • Age between 18 and 55 years
  • Diagnosed with chondral defects (cartilage damage) in the weight-bearing part of the knee joint
  • The defect is located in the weight-bearing part of the femoral condyle (the end of the thigh bone that forms part of the knee joint)
  • The cartilage defect is no larger than 6 cm²
  • No previous knee surgery for treating a cartilage defect

There are also several conditions that would prevent someone from participating in the study, such as certain infections, cancer, or pregnancy.

Treatment Procedure

The treatment involves several steps:[1]

  1. Bone marrow is collected from the patient
  2. Stem cells are isolated and grown in a laboratory
  3. The patient undergoes knee surgery (microfracture)
  4. The expanded stem cells are placed on a 3D scaffold
  5. The scaffold with stem cells is applied to the damaged area in the knee

The maximum dose of LENZUMESTROCEL used in the study is 5,500,000 cells, given as a single treatment.[1]

Expected Outcomes

The researchers will measure the success of the treatment in several ways:[1]

  • Lysholm knee function score: This measures how well your knee functions in daily activities
  • KOOS (Knee Injury and Osteoarthritis Outcome Score): This assesses pain, symptoms, daily function, sports activities, and quality of life related to your knee
  • Pain levels using a VAS (Visual Analog Scale)
  • X-ray and MRI evaluations of the knee

These measurements will be taken at various points over two years to track progress and compare the results between the two treatment groups.

Safety Considerations

While LENZUMESTROCEL has shown promising results in earlier studies, this trial will continue to monitor its safety. Patients will be checked for any adverse events (side effects or complications) throughout the study period.[1]

It’s important to note that this is still an experimental treatment. If you’re considering participating in this or any clinical trial, always discuss it thoroughly with your doctor to understand the potential risks and benefits.

Aspect Details
Drug Name Lenzumestrocel (BiCure ortho MSCp)
Trial Phase Phase IIb
Condition Studied Knee Cartilage Defect
Main Objective Compare efficacy of Lenzumestrocel with microfracture and 3D scaffold vs. microfracture and scaffold alone
Key Inclusion Criteria Adults 18-55 years, chondral defects up to 6 cm², no previous knee surgery for chondral defect
Primary Endpoints Lysholm score, KOOS value, Pain (VAS), X-ray and MRI evaluation at 24 months post-operation
Administration Suspension for injection in pre-filled syringe, intracartilaginous use
Follow-up Duration 24 months

FAQ

  • What is Lenzumestrocel? Lenzumestrocel is a type of cell therapy that uses a patient's own bone marrow-derived mesenchymal stem cells. It's being studied as a potential treatment for knee cartilage defects.
  • How is Lenzumestrocel administered? Lenzumestrocel is administered as a suspension for injection in a pre-filled syringe. In the clinical trial, it's combined with a conventional microfracture procedure and applied using a 3D scaffold in the knee joint.
  • Who can participate in the Lenzumestrocel clinical trial? The trial is open to adults aged 18-55 with confirmed chondral defects in the weight-bearing part of the knee joint. Participants must meet specific criteria, including having a defect size of up to 6 cm² and no previous knee surgery for chondral defect treatment.
  • What are the main goals of the Lenzumestrocel clinical trial? The primary goal is to compare the efficacy of Lenzumestrocel combined with microfracture and a 3D scaffold to the standard microfracture with scaffold alone. The trial also aims to collect safety data on the use of autologous mesenchymal stem cells.
  • How long does the Lenzumestrocel clinical trial last? The trial follows participants for up to 24 months after the operation. Key assessments are made at various time points, including 3, 6, 12, and 24 months post-operation, to evaluate the treatment's effectiveness and safety.

Ongoing Clinical Trials on Lenzumestrocel

  • Study on the Effectiveness of Lenzumestrocel for Treating Knee Cartilage Defects in Patients

    Recruiting

    1 1
    Investigated drugs:
    Czechia

Glossary

  • Lenzumestrocel: A type of cell therapy using a patient's own bone marrow-derived mesenchymal stem cells, being studied for treating knee cartilage defects.
  • Chondral defect: Damage to the cartilage in a joint, in this case, the knee joint.
  • Microfracture: A surgical technique used to treat cartilage defects by creating small holes in the underlying bone to promote new cartilage growth.
  • 3D scaffold: A structure used in tissue engineering to provide support for cells to grow and form new tissue.
  • Autologous: Derived from the same individual, referring to the patient's own cells used in the treatment.
  • Mesenchymal stem cells (MSCs): A type of adult stem cell that can develop into various cell types, including cartilage cells.
  • Lysholm knee function score: A scoring system used to evaluate knee function and symptoms in patients with knee injuries.
  • KOOS (Knee Injury and Osteoarthritis Outcome Score): A questionnaire used to assess the patient's opinion about their knee and associated problems.
  • VAS (Visual Analog Scale): A measurement tool used to assess pain intensity on a continuous scale.
  • Osteoarthrosis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lenzumestrocel-for-treating-knee-cartilage-defects-in-patients/